Allowing a forum for patients to give FDA information about their disease has proven popular, but a question remaining for the patient-focused drug development program as it continues to grow is how that information will be used.
Patient-Focused Drug Development At 10: Where Does It Go From Here?
FDA may conduct more than the 20 required meetings by the end of fiscal year 2017, but how will the patient-focused drug development program find its place in helping generate new drugs?